The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: CPC

Monday Biotech Deal Review: April 26, 2010

This week’s deals are highlighted by a new TSX-V listed biotech, a $16 million D round, five collaborations a FedDev win for Bioniche, and updates on this month’s flurry of financings. Read more of this post

Toronto Stock Exchange (TSX) Temporary Relief Extended

The TSX and TSX-V temporary relief measures have been extended through September 30, 2009.  Specifically:

  • Toronto Stock Exchange has extended the remedial review period for delistings from a maximum of up to 120 days to up to 210 days.
  • TSX Venture Exchange’s temporary relief measures include:
    • adding flexibility in how existing continued listing requirements are applied to listed issuers;
    • extending the time within which Capital Pool Companies® can complete their qualifying transactions, and
    • allowing the minimum issuance price per security in certain transactions to be less than $0.05 (but not less than the market price).

Bookmark and Share

Follow

Get every new post delivered to your Inbox.

Join 129 other followers